- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
LIFE Trial: sacubitril/valsartan combination not effective to treat HF - Video
Overview
The LIFE trial highlights that combination sacubitril/valsartan did not reduce N-terminal pro b-type natriuretic peptide (NT-proBNP) or clinical outcomes among patients with advanced heart failure with reduced ejection fraction and comorbidities. Heart failure can develop suddenly or over time causing cardiac death which is a leading cause of death globally. Several medications are being evaluated to manage heart failure.
The trial aimed to assess the efficacy and safety of sacubitril/valsartan compared with valsartan in patients with advanced heart failure with reduced ejection fraction. 167 patients were randomized in a 1:1 ratio to either sacubitril/valsartan starting dose 24/26 mg or 49/51 mg twice a day, to 97/103 mg increased twice a day if tolerated after 4 weeks, or valsartan starting dose 40 or 80 mg twice a day.
Drugs didn't improve mortality and cardiovascular events, days alive outside hospital was 103.2 vs. 111.2 days, published in American College of Cardiology the results of this trial indicate that the combination sacubitril/valsartan did not reduce NT-proBNP or clinical outcomes among patients with advanced heart failure with reduced ejection fraction and comorbidities.
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)